English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA researcher at The University of Alabama in Huntsville (UAH) has been awarded a $179,000 subcontract to explore community-based strategies for reducing high-burden chronic disease like obesity, diabetes, heart disease and cancer as part of an overall award totaling $4.2 million.
Tag: cardiometabolic disease
Globally, Consumption of Sugary Drinks Increased at Least 16% Since 1990
The decision to reach for a sugar sweetened beverage is heavily influenced by where you live, Tufts University researchers report in a new study that provides a snapshot of how adults in 185 countries imbibe sugar-sweetened beverages.
UCSF Internal Medicine Specialist to be Celebrated for Diabetes Epidemiology Research
Alka M. Kanaya, MD, UC San Francisco primary care physician and researcher, is being recognized with the 2023 Kelly West Award for Outstanding Achievement in Epidemiology from the American Diabetes Association (ADA). The award recognizes significant contributions to the field of diabetes epidemiology.
Biases in cardiometabolic research put minority women’s lives at risk
Biases in heart disease and metabolic disorder—also known as cardiometabolic—studies are putting the lives of midlife Black and Hispanic women in jeopardy.
Eating Whole Grains Linked to Smaller Increases in Waist Size, Blood Pressure, Blood Sugar
A study finds middle- to older-aged adults who ate more servings of whole grains, compared to those who ate fewer, were more likely to have smaller increases in waist size, blood pressure, and blood sugar levels as they aged. All three are linked with increased risk of heart disease.
Wayne State University and Henry Ford Health System announce new initiative in cardiometabolic health and disease
Wayne State University and Henry Ford Health System announced today the launch of a basic and translational research initiative in Cardiometabolic Health and Disease as a thematic focus for program growth.
A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.